Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9BY79
UPID:
MFRP_HUMAN
Alternative names:
Membrane-type frizzled-related protein
Alternative UPACC:
Q9BY79; B0YJ36; B0YJ37; B4DHN8; Q335M3; Q96DQ9
Background:
The Membrane frizzled-related protein, alternatively known as Membrane-type frizzled-related protein, plays a pivotal role in eye development. This protein, encoded by the gene with the accession number Q9BY79, is crucial for the proper formation and function of the eyes.
Therapeutic significance:
Linked to rare eye disorders such as Nanophthalmos 2 and Microphthalmia, isolated, 5, the Membrane frizzled-related protein's involvement in these conditions underscores its potential as a target for therapeutic intervention. Understanding the role of Membrane frizzled-related protein could open doors to potential therapeutic strategies.